报告题目：化学调控甲基化酶及在表观遗传中的应用
报告人：Prof. Minkui Luo
Memorial Sloan Kettering Cancer Center & Weill Cornell Medical College
报告时间：2015年 6月22日（星期一）10：00 AM
报告地点：独墅湖校区二期云轩楼2301室
Abstract
Protein methyltransferases (PMTs) are involved in numerous epigenetic processes. Their dysregulation has been implicated in many diseases including cancer. Among >60 PMTs in human, most of them remain to be characterized. The oncogenic roles of certain PMTs were implicated via methylation-mediated dysregulation of oncogenes or tumor suppressors, and thus present these PMTs as emerging anti-cancer targets. However, pharmacological perturbation of these PMTs requires high-quality chemical probes with few documented in literature. These situations therefore intrigued the Luo laboratory to focus on two projects: (1) developing the novel Bioorthogonal Profiling of Protein Methylation (BPPM) technology to profile proteome-wide/genome-wide methylation of designated PMTs; (2) developing potent, target-specific inhibitors as pharmacological modulators of PMTs. The presentation will outline the journey of the Luo laboratory to develop unconventional tools and apply them to interrogate PMTs.
Introduction of the Speaker
Minkui Luo obtained his B.S. degree in organic chemistry at Fudan University in 1999. He then traveled to the U.S to pursue his Ph.D in the field of bioorganic and bioinorganic chemistry under the guidance of Dr. John T. Groves, at Princeton University. Then, in 2005, he joined the laboratory of Dr. Vern Schramm as a postdoctoral fellow at the Albert Einstein College of Medicine. In 2008, he started his independent career at the Memorial Sloan-Kettering Cancer Center and Weill Cornell Medical College (joint appointment). The current research in the Luo laboratory focuses on developing and implementing chemical tools to define, perturb and manipulate epigenetic functions of protein methyltransferases for disease diagnosis and therapy. Dr. Luo have published many peer-reviewed papers in international prestigious journals and received several well-recognized awards, such as ACS Eli Lilly Award of Biological Chemistry (2015), CTSC Novel Award (2014), Basil O'Connor Starter Scholar (2011), 2010 NIH Director’s New Innovator Award, Alfred W. Bressler Scholar (2010), the V Scholar Award for Cancer Research (2009) and the Outstanding Postdoctoral Research Prize (2007).
